文献速递肝肾功能剂量调整抗栓抗凝管理特殊人群用药

慢性肾脏病患者的抗凝治疗

Anticoagulation in Chronic Kidney Disease.
PubMed 文献 · Drugs · 2024-08-09

本文综述慢性肾脏病(CKD)患者抗凝治疗的复杂挑战,涉及出血与血栓双重风险、剂量调整与监测需求。直接口服抗凝药(DOACs)为未透析患者带来新选择,但在晚期CKD中应用仍不确定。左心耳封堵(LAAO)等新策略可能为高卒中风险患者提供个体化方案。

要点

  • CKD患者抗凝需平衡出血与血栓风险,并依据肾功能调整剂量和监测。
  • DOACs在未透析CKD患者中管理更便捷,但晚期CKD证据有限。
  • LAAO可能为CKD合并高卒中风险患者提供替代策略,但需进一步研究。

核心结论

  • CKD患者抗凝治疗需精细平衡出血与血栓风险,结合剂量调整、监测及新疗法个体化决策。

研究设计与样本

  • 综述,检索范围未报告。

主要发现

  • CKD患者因血小板功能受损和凝血系统紊乱同时面临出血和血栓风险。
  • CKD改变药物药代动力学,清除受阻增加药物蓄积和不良反应风险。
  • DOACs管理更简便且减少监测需求,但晚期CKD应用仍属未知领域。
  • LAAO可能为CKD合并高卒中风险患者提供个体化选择。

临床怎么用

  • CKD患者使用抗凝药需根据肾功能调整剂量并加强监测。
  • 未透析CKD患者可考虑DOACs,但晚期CKD需谨慎评估。
  • 高卒中风险的CKD患者可个体化考虑LAAO。

局限性

  • DOACs在晚期CKD中的疗效与安全性证据不足。
  • LAAO在CKD患者中的效用和安全性尚需研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The nuanced landscape of anticoagulation therapy in patients with chronic kidney disease (CKD) presents a formidable challenge, intricately balancing the dual hazards of hemorrhage and thrombosis. These patients find themselves in a precarious position, teetering on the edge of these risks due to compromised platelet functionality and systemic disturbances within their coagulation frameworks. The management of such patients necessitates a meticulous approach to dosing adjustments and vigilant monitoring to navigate the perilous waters of anticoagulant therapy. This is especially critical considering the altered pharmacokinetics in CKD, where the clearance of drugs is significantly impeded, heightening the risk of accumulation and adverse effects. In the evolving narrative of anticoagulation therapy, the introduction of direct oral anticoagulants (DOACs) has heralded a new era, offering a glimmer of hope for those navigating the complexities of CKD. These agents, with their promise of easier management and a reduced need for monitoring, have begun to reshape the contours of care, particularly for patients not yet on dialysis. However, this is not without its caveats. The application of DOACs in the context of advanced CKD remains a largely uncharted territory, necessitating a cautious exploration to unearth their true potential and limitations. Moreover, the advent of innovative strategies such as left atrial appendage occlusion (LAAO) underscores the dynamic nature of anticoagulation therapy, potentially offering a tailored solution for those at the intersection of CKD and elevated stroke risk. Yet the journey toward integrating such advancements into standard practice is laden with unanswered questions, demanding rigorous investigation to illuminate their efficacy and safety across the spectrum of kidney disease. In summary, the management of anticoagulation in CKD is a delicate dance, requiring a harmonious blend of precision, caution, and innovation. As we venture further into this complex domain, we must build upon our current understanding, embracing both emerging therapies and the need for ongoing research. Only then can we hope to offer our patients a path that navigates the narrow strait between bleeding and clotting, toward safer and more effective care.

来源:Drugs,查看原文。版权归原作者所有。

引用

  1. Montomoli M, Candía BG, Barrios AA, et al. Anticoagulation in Chronic Kidney Disease. Drugs. 2024. PMID: 39120783. doi:10.1007/s40265-024-02077-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。